Contribute Try STAT+ Today

A gene therapy from Voyager Therapeutics (VYGR) delivered surgically into the brains of patients with advanced Parkinson’s disease reduced their need for standard Parkinson’s medications and improved motor function, according to results from a small, early-stage clinical trial reported Wednesday.

Unlike most gene therapies for inherited disease in clinical development, the Voyager treatment does not aim to cure Parkinson’s — because nothing yet invented can fully prevent the loss of neurons in the brain. Instead, Voyager’s gene therapy acts like a biological detour around dead neurons, so Parkinson’s patients respond better and longer to levodopa, the standard drug used to keep motor function under control.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.